Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.46, delivering a surprise of -24.32%. Over the last four quarters, the company ha ...